Loading...

Novo Nordisk A/S

NONOFPNK
Healthcare
Biotechnology
$66.06
$1.55(2.40%)

Novo Nordisk A/S (NONOF) Company Profile & Overview

Explore Novo Nordisk A/S’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Novo Nordisk A/S (NONOF) Company Profile & Overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

SectorHealthcare
IndustryBiotechnology
CEOLars Fruergaard Jorgensen

Contact Information

45 44 44 88 88
Novo Allé 1, Bagsvaerd, 2880

Company Facts

77,406 Employees
IPO DateMay 7, 2010
CountryDK
Actively Trading

Frequently Asked Questions

;